DDInter1568 DDInter1435
Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Ranitidine {u} (Compound) resembles {v} (Compound) Nizatidine
Ranitidine {u} (Compound) binds {v} (Gene) CYP3A4
Ranitidine {u} (Compound) upregulates {v} (Gene) GPATCH8
Ranitidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Ranitidine {u} (Compound) downregulates {v} (Gene) SDC1
Ranitidine {u} (Compound) causes {v} (Side Effect) Weight decreased
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Etodolac
Ranitidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tubocurarine
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Ranitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Ranitidine (Compound) resembles Nizatidine (Compound)
Ranitidine (Compound) binds CYP3A4 (Gene)
Ranitidine (Compound) upregulates GPATCH8 (Gene)
Ranitidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Ranitidine (Compound) downregulates SDC1 (Gene)
Ranitidine (Compound) causes Weight decreased (Side Effect)
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Etodolac
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Tubocurarine
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline